Metformin has been in clinical use since 1957 and approved in the United States since 1995, giving us more long term safety data than almost any other prescription medication. Over 150 million people worldwide take it daily. Yet patient concerns about long term use are common and often not evidence based. Here is what the research actually shows, separating established risks from internet myths.
How metformin works
Metformin belongs to the biguanide class. Its primary mechanism is reducing glucose production by the liver (hepatic gluconeogenesis). It also mildly improves insulin sensitivity in peripheral tissues and reduces intestinal glucose absorption.
Importantly, metformin does not cause hypoglycemia when used alone. It reduces excess glucose production but does not stimulate insulin secretion. This is one of its safest features and why it is first line therapy for most Type 2 diabetes patients.
In India, metformin is marketed under over 50 brand names including Glycomet (Mankind), Gluformin (Sanofi), Obimet (Abbott), Glucophage (Merck), and Diamet (Bestochem). A typical monthly cost ranges from Rs. 25 to Rs. 180 depending on dose and brand.
Established uses
Metformin is primary therapy for:
- Type 2 diabetes: First line drug in all major international guidelines including ADA, ICMR, and IDF
- Prediabetes: Off label in many countries but widely used when lifestyle alone fails to normalize HbA1c
- PCOS: For insulin resistance and ovulation induction, especially when clomiphene resistance is present
- Gestational diabetes: Selective use, primarily in obese women who cannot tolerate insulin
- Weight management with insulin resistance: Adjunct to lifestyle intervention
The vitamin B12 issue
This is the most established long term concern with metformin. Multiple long term studies show that 10 to 30 percent of long term metformin users develop biochemical vitamin B12 deficiency. The risk increases with dose and duration of therapy.
The mechanism is not entirely clear but likely involves altered calcium dependent B12 absorption in the terminal ileum. B12 deficiency can cause peripheral neuropathy, cognitive changes, and megaloblastic anemia.
What to do
Check serum B12 annually if you have been on metformin for 5 years or more. Threshold for supplementation varies by lab, but B12 levels below 300 pg per ml typically warrant oral supplementation with 1000 mcg daily. Below 200 pg per ml requires prompt supplementation and evaluation for neurological symptoms. Injectable B12 (cyanocobalamin or methylcobalamin 1000 mcg monthly) may be preferred for severe deficiency or malabsorption.
Consider baseline B12 check before starting long term metformin, especially in vegetarians (many Indian patients), older adults, and patients with GI disorders.
Kidney function
This is the most misunderstood concern. Metformin does not cause kidney damage. This is a persistent myth.
Metformin is eliminated by the kidneys. In severe kidney disease, metformin can accumulate and potentially cause lactic acidosis. This is why metformin is contraindicated in severe kidney impairment, not because it harms the kidneys.
Current guidelines for metformin use by kidney function:
- eGFR above 60: Use normally, full dose
- eGFR 45 to 59: Use with caution, monitor every 6 months
- eGFR 30 to 44: Reduce dose to 1000 mg maximum daily, monitor closely
- eGFR below 30: Contraindicated, discontinue metformin
Some studies actually suggest a protective effect of metformin on kidney function in diabetes, possibly through reduced oxidative stress and improved glycemic control.
Lactic acidosis
This was a major concern with phenformin, a related biguanide withdrawn in 1977. Metformin associated lactic acidosis is rare: approximately 3 to 10 cases per 100,000 patient years.
When it does occur, it is almost always in patients who should not have been on metformin in the first place: severe kidney disease, severe liver disease, acute illness causing hypoperfusion, or sepsis. True metformin toxicity in appropriately selected patients is extraordinarily rare.
Temporary discontinuation is recommended during:
- Acute severe illness especially with dehydration
- Contrast imaging studies
- Major surgery
- Acute kidney injury
Gastrointestinal side effects
The most common side effects of metformin are gastrointestinal: nausea, diarrhea, abdominal discomfort, and metallic taste. These affect 20 to 30 percent of patients when starting therapy.
Strategies to minimize GI side effects:
- Start low (500 mg once daily with dinner) and titrate up slowly over 2 to 4 weeks
- Take with food, preferably the largest meal
- Consider extended release formulations which have better GI tolerance
- Avoid taking on empty stomach
Most GI side effects resolve within 2 to 4 weeks of continued use. If they persist, extended release metformin often solves the problem.
Weight effects
Metformin is weight neutral or mildly weight reducing in most patients. This is a distinct advantage over older diabetes medications like sulfonylureas or insulin which typically cause weight gain.
Expected weight effect: 1 to 3 kg weight loss in the first 6 months, then stable. This is modest but meaningful in a patient population that tends toward obesity.
Cancer and metformin
Observational studies have suggested that metformin users have lower rates of several cancers including breast, colon, and pancreatic cancer. However, these findings have not been consistently replicated in randomized trials. The current consensus is that metformin probably does not cause cancer protection, but the signal is being actively investigated.
Longevity and anti aging research
The TAME trial (Targeting Aging with Metformin) is an ongoing large scale study investigating whether metformin can delay aging related diseases in non diabetic adults. Early observational data suggests metformin users may have lower all cause mortality than expected, though this could be explained by healthier user bias.
Proposed mechanisms include improved mitochondrial function, reduced oxidative stress, activation of AMPK signaling, and improvements in gut microbiome. As of 2026, metformin for longevity remains experimental. Off label use for this indication in otherwise healthy individuals is not supported by current evidence.
Contraindications and precautions
Do not use metformin if you have:
- eGFR below 30 ml per min per 1.73 m2
- Acute metabolic acidosis including diabetic ketoacidosis
- Severe liver dysfunction with potential lactate accumulation
- Active alcohol abuse
- Unstable heart failure with tissue hypoxia
Relative caution in:
- Older adults (use lower doses initially)
- History of lactic acidosis
- Recent major surgery
- Radiographic contrast exposure within 48 hours
Drug interactions
Metformin has relatively few clinically important drug interactions. Notable ones include:
- Alcohol: Increases lactic acidosis risk, especially in binge drinking
- Iodinated contrast agents: Temporarily withhold for 48 hours after administration if kidney function is impaired
- Loop diuretics and dehydration states: Can reduce kidney clearance of metformin
- Cimetidine: Modestly increases metformin blood levels
My clinical take after reviewing the evidence
Metformin is one of the safest chronic medications ever developed. The concerns that patients bring up most often, kidney damage and liver damage, are not supported by evidence. The genuine concerns, vitamin B12 deficiency and rare lactic acidosis in misselected patients, are easily managed with appropriate monitoring and patient selection.
For a newly diagnosed Type 2 diabetic, metformin is almost always the right starting medication. For PCOS with insulin resistance, it is often the most effective single intervention beyond lifestyle. For prediabetes with continued progression despite lifestyle change, it is an increasingly common and reasonable choice.
The long term data simply does not support most of the fear around this drug. After 70 years and hundreds of millions of patient years, we would have seen any serious hidden harm by now.